SCHEMBL25340450

SCHEMBL25340450

COC(=O)c1cc(O)c(I)cc1C(=O)OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.50
CA1 P00915 5/20 0.50
CA2 P00918 5/20 0.50
CA7 P43166 5/20 0.50
CA9 Q16790 5/20 0.50
CA14 Q9ULX7 5/20 0.50
PDK2 Q15119 1/20 0.50
PDK4 Q16654 1/20 0.50
LMNA P02545 2/20 0.48
TSHR P16473 1/20 0.48
CFTR P13569 2/20 0.47
GAA P10253 4/20 0.47
KDM4E B2RXH2 3/20 0.45
XDH P47989 2/20 0.45
POLB P06746 2/20 0.45
NFKB1 P19838 1/20 0.45
GFER P55789 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
FUT7 Q11130 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31024714 1.00 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL15903170 0.87 CFTR (0.53) CA12CA1CA2CA7CA9
SCHEMBL30345042 0.86 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL25155265 0.86 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL1764082 0.86 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL17892934 0.85 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL31431621 0.85 CA1 (0.44) CA12CA1CA2CA7CA9
SCHEMBL31187062 0.85 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL31216058 0.85 CFTR (0.58) CA12CA1CA2CA7CA9
SCHEMBL10200826 0.85 CFTR (0.46) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR GAN & LEE PHARMACEUTICALS CO., LTD. (CN) 2025-04-24 US disclosed
EP-4471033-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR Gan & Lee Pharmaceuticals Co., Ltd. (CN) 2024-12-04 EP disclosed
WO-2023143589-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR 甘李药业股份有限公司 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR CRBN, UBE3A, UBE3C CA12 1839/4885CA1 691/4885CA2 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.